Karyopharm Therapeutics has granted the Menarini Group exclusive rights to commercialize NEXPOVIO in Europe, Latin America and other key countries. NEXPOVIO is indicated for the treatment of multiple myeloma in adults. Karyopharm will receive $75 million, as well as up to another $202.5 million when the drug's future development milestones are achieved and tiered double-digit royalties from net sales.